Left Ventricular Ejection Fraction (LVEF) Archives

FDA approves Bristol Myers’ oral heart disease drug

Approvals, Boxed Warning, Bristol Myers Squibb, Cardiac Arrest, Cardiac myosin inhibitors, FDA, Genetic Inflammatory Conditions, Heart Disease, Heart Muscles, Hypertrophic cardiomyopathy (HCM), Left Ventricular Ejection Fraction (LVEF), Oral Therapy, Therapeutics, Wholesale Acquisition Cost

The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.

April 28, 2022/by Reuters Health

Entresto granted expanded indication in chronic heart failure by FDA

Blockbusters, Chronic Heart Failure, Expanded Indication, FDA, Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure with Reduced Ejection Fraction (HFrEF), Label Expansion, Left Ventricular Ejection Fraction (LVEF), Novartis, Therapeutics

Novartis’ Entresto is the first therapy approved in the United States to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).

February 16, 2021/by Andrew Humphreys